GRK2-YAP信号与肺动脉高血压的发展有关
Peng Ye1, Yunfei Deng2,3, Yue Gu2
1Division of Cardiovascular Molecular Laboratory, Third Clinical College, Nanjing Medical University, Nanjing, Jiangsu 210006, China.
G蛋白结合受体激酶2 (GRK2) 在肺动脉高血压 (PAH) 中被上调,并通过促进光滑肌肉细胞增殖来驱动疾病的进展. 向GRK2可能为PAH提供新的治疗策略.
科学领域:
- 心血管研究研究心血管研究
- 分子生物学分子生物学
- 细胞生物学 细胞生物学
背景情况:
- 肺动脉高血压 (PAH) 涉及肺动脉光滑肌细胞 (PASMCs) 的过度增殖.
- G蛋白结合受体激酶2 (GRK2) 对于血管度至关重要,但其在PAH中的作用尚不清楚.
研究的目的:
- 调查GRK2在肺动脉高血压 (PAH) 病变发生中的作用.
- 确定GRK2是否是PAH的潜在治疗标.
主要方法:
- 在人类PAH肺组织和实验性肺高血压 (PH) 鼠标模型中评估GRK2水平.
- 利用了血管光滑肌细胞特异性的GRK2淘汰小鼠和体外PASMC研究.
- 研究了GRK2对YES相关蛋白 (YAP) 表达和转位的影响.
主要成果:
- 在PAH患者和PH小鼠中,GRK2表达升高.
- 在小鼠中,GRK2淘汰赛减弱PH和肺血管重塑.
- 抑制GRK2倒置,而过度表达加剧,低氧诱导的PASMC增殖和迁移.
- 通过对YAP表达和核转移进行升级调节,GRK2促进了PASMC的扩散和迁移.
结论:
- 通过调节YAP,GRK2在PAH的发病过程中发挥着关键作用.
- GRK2代表了治疗PAH的新型治疗标.
更多相关视频
10:32Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs
Published on: December 19, 2019
09:23Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension
Published on: February 11, 2017
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
The JAK-STAT Signaling Pathway
MAPK Signaling Cascades
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
Regulation of Angiogenesis and Blood Supply
